We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-8.25%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$3.75B
AUM Growth
-$833M
Cap. Flow
-$27.3M
Cap. Flow %
-0.73%
Top 10 Hldgs %
47.18%
Holding
110
New
14
Increased
9
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
VERU icon
Veru
VERU
+$91.7M
2
PEPG icon
PepGen
PEPG
+$90.7M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$66.8M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$36.2M
5
NKTX icon
Nkarta
NKTX
+$28.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$60.4M
2
MGNX icon
MacroGenics
MGNX
+$53.8M
3
NVAX icon
Novavax
NVAX
+$51M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$32.1M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
26
Natera
NTRA
$38.6B
$46.4M 1.24%
1,310,289
– –
ABOS icon
27
Acumen Pharmaceuticals
ABOS
$157M
$45.9M 1.22%
9,770,773
– –
NSTG
28
DELISTED
NanoString Technologies, Inc.
NSTG
$45.5M 1.21%
+3,584,478
New +$66.8M
RXST icon
29
RxSight
RXST
$252M
$43M 1.15%
3,052,796
– –
ENTA icon
30
Enanta Pharmaceuticals
ENTA
$378M
$42.4M 1.13%
896,724
-67,488
-7% -$3.66M
CLYM
31
Climb Bio
CLYM
$692M
$39.7M 1.06%
13,150,849
– –
RLMD icon
32
Relmada Therapeutics
RLMD
$562M
$38M 1.01%
2,000,000
– –
TIL icon
33
Instil Bio
TIL
$48.4M
$35.4M 0.94%
383,540
+140,000
+57% +$19.8M
ICVX
34
DELISTED
Icosavax, Inc. Common Stock
ICVX
$34.2M 0.91%
5,963,565
– –
RNAM
35
DELISTED
Avidity Biosciences
RNAM
$31.5M 0.84%
2,167,391
– –
DSGN icon
36
Design Therapeutics
DSGN
$788M
$30.6M 0.82%
2,186,636
– –
ANTX icon
37
AN2 Therapeutics
ANTX
$192M
$29.1M 0.77%
3,748,389
+81,726
+2% +$1.08M
RCKT icon
38
Rocket Pharmaceuticals
RCKT
$351M
$29M 0.77%
2,107,149
– –
EYPT icon
39
EyePoint Inc
EYPT
$1.08B
$26.5M 0.71%
3,370,506
– –
ETNB
40
DELISTED
89bio
ETNB
$25.1M 0.67%
7,782,669
+2,816,900
+57% +$8.5M
STSA
41
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$24.5M 0.65%
5,914,252
– –
PMVP icon
42
PMV Pharmaceuticals
PMVP
$60.3M
$24.4M 0.65%
1,710,265
– –
VERA icon
43
Vera Therapeutics
VERA
$2.37B
$21.5M 0.57%
1,578,820
-387,264
-20% -$6.76M
VRNA
44
DELISTED
Verona Pharma
VRNA
$21.4M 0.57%
5,100,000
– –
RYTM icon
45
Rhythm Pharmaceuticals
RYTM
$7.25B
$20.2M 0.54%
4,871,067
– –
TNYA icon
46
Tenaya Therapeutics
TNYA
$163M
$20M 0.53%
3,551,508
– –
DYN icon
47
Dyne Therapeutics
DYN
$4.8B
$19.3M 0.51%
2,805,045
– –
HLVX
48
DELISTED
HilleVax
HLVX
$19.2M 0.51%
+1,760,019
New +$20.9M
GH icon
49
Guardant Health
GH
$20.2B
$19.2M 0.51%
476,380
– –
PRDS
50
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$19M 0.51%
6,175,038
– –
1
2
3 4 5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, RA Capital Management held 110 positions worth $3.75B, down 18% from $4.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

RA Capital Management's Q2 2022 filing shows 14 new, 9 increased, 11 reduced and 22 closed positions. Its largest new stake was Veru: 790,000 shares worth $89.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $60.4M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q2 2022 buy was Veru: 790,000 shares worth $89.3M.
  • RA Capital Management added most to Aclaris Therapeutics in Q2 2022, an estimated $36.2M increase.
  • RA Capital Management's biggest Q2 2022 reduction was LianBio American Depositary Shares, cutting an estimated $10.3M.
  • RA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $60.4M.
  • RA Capital Management's ten largest holdings make up 47% of its $3.75B portfolio in Q2 2022.
  • RA Capital Management opened 14 new positions and closed 22 in Q2 2022.
  • RA Capital Management's portfolio value fell 18% quarter-over-quarter to $3.75B.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.